comparemela.com

Latest Breaking News On - Courtesy of abbvie inc - Page 1 : comparemela.com

AbbVie s Humira Sales Sink 36% but Guidance Lifted on Growth From Other Drugs

The biopharmaceuticals company raised its earnings forecast for fiscal 2023.

Richard gonzalezAngela palumboCourtesy of abbvie incAbbvie incExecutive richard gonzalezArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceSales figuresEarnings projectionsCorporate actionsCorporate industrial newsContent typesFactiva filtersC amp ampe exclusion filter

AbbVie and Sosei Lead Slate of Early August R&D Deals

AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

Matt barnesXenetic dnaseTherapeuticsand menarini groupannouncedJeffrey eisenbergSendurai maniXenetic biosciencesSosei group corporationCourtesy of abbvie incAbbvie incUniversity of texas md anderson cancer centertoSosei add neurological targetsNew dealGroup corporationHeptare starTranscode therapeuticsCancer centerto

AbbVie s Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn s Disease

The FDA's decision is based on positive results from two induction and one maintenance clinical study of AbbVie's Skyrizi for Crohn's disease.

Thomas hudsonAbbvie skyriziDerick gonzalesCourtesy of abbvie incAbbvie incDrug administrationSimple endoscopic scoreDisease activity indexVie chairmanChief executive rick gonzalesBbvie 39s skyrizi becomes first fda approved il 23 inhibitor for crohn disease

vimarsana © 2020. All Rights Reserved.